Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/109602
Title: Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals
Author: Kawana-Tachikawa, Ai
Llibre, Josep M.
Bravo, Isabel
Escrig, Roser
Mothe, Beatriz
Puig, Jordi
Puertas, Maria C.
Martínez Picado, Francisco Javier
Blanco, Julia
Manzardo, Christian
Miró Meda, José M.
Iwamoto, Aikichi
Pozniak, Anton L.
Gatell, José M.
Clotet i Sala, Bonaventura
Brander, Christian
Keywords: Cèl·lules T
VIH (Virus)
Antiretrovirals
Resposta immunitària
Genètica molecular
T cells
HIV (Viruses)
Antiretroviral agents
Immune response
Molecular genetics
Issue Date: 27-Jan-2014
Publisher: Public Library of Science (PLoS)
Abstract: BACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). RESULTS: Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups. CONCLUSIONS: Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.
Note: Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0087334
It is part of: PLoS One, 2014, vol. 9, num. 1, p. e87334
Related resource: https://doi.org/10.1371/journal.pone.0087334
URI: http://hdl.handle.net/2445/109602
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
641597.pdf844.68 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons